Skip to main content
. 2021 May 5;12:642180. doi: 10.3389/fimmu.2021.642180

Figure 5.

Figure 5

(A) Changes in sweat chloride prior to and during ivacaftor therapy (p = 0.008). Baseline mean: 96.31 ± 14.34 (median: 92.50, IQR=24.38) mmol/L. Mean after three months of therapy initiation: 40.10 ± 13.85 (median: 46.50, IQR=25.10) mmol/L. (B) Changes in FEV1 prior and during ivacaftor therapy (p=0.016). Baseline mean: 99.7 ± 20.3% predicted, (median: 103.6% predicted, IQR=20.4% predicted). Mean after three months of therapy initiation: 107.6 ± 21.4%pred (median: 109.6% predicted, IQR=18.4% predicted).